From the WSJ:
Federal prosecutors in Washington, D.C., have rejected a roughly $1 billion proposed settlement to resolve allegations that Johnson & Johnson promoted the antipsychotic drug Risperdal for unapproved uses, according to people familiar with the matter.
http://online.wsj.com/article/SB10001424052970203961204577271754076678044.html?ru=yahoo&mod=yahoo_hs
